{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56","upperLimit":"129","value":"83"},{"groupId":"OG001","lowerLimit":"7","upperLimit":"460","value":"109"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Duration of response was defined as the time from first notation of response until the time of first notation of disease progression.","dispersionType":"Full Range","groups":[{"description":"CTCL patients will receive 1000 mg/m2 of PXD101 IV\n\nbelinostat: 1000 mg/m2 for 5 days every 21 days; IV","id":"OG000","title":"Arm A (CTCL, ITT Population)"},{"description":"PTCL patients will receive 1000 mg/m2 of PXD101 IV\n\nbelinostat: 1000 mg/m2 for 5 days every 21 days; IV","id":"OG001","title":"Arm B (PTCL, ITT Population)"}],"paramType":"MEDIAN","populationDescription":"Duration of response (ITT population) was estimated by Kaplan-Meier method for CTCL/PTCL arms. 2 CTCL and 2 PTCL patients did not progress and were censored. Median duration of response and full range (days) are presented for 2 patients with CTCL and 4 patients with PTCL. The 2 CTCL patients being evaluable had response durations of 56 and 129 days","reportingStatus":"POSTED","timeFrame":"throughout the study, or for a maximum of 2 years","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"Days"}